[e Gongsi Notice Catches Attention] KOSDAQ - 17th

▲ M2N = Pacylex's 'PCLX-001' was designated as an orphan drug by the U.S. Food and Drug Administration (FDA) on the 15th (local time) for the treatment of acute myeloid leukemia patients. PCLX-001 is an N-myristoyltransferase (NMT) inhibitor currently in Phase 1 clinical trials in Canada by Pacylex.

▲ iWinPlus = The largest shareholder iWin and CEO Shin Gyu-jin of iWin each acquired 3,115,869 shares and 197,049 shares of iWinPlus, respectively. The company explained that the additional stock acquisition aims to enhance shareholder value considering the company's growth potential.

▲ Surplus Global = Decided to enter into a trust contract for the acquisition of treasury shares worth 1 billion KRW to stabilize stock price and enhance shareholder value. The contracting institution is Daishin Securities. The contract period is from today until April 17 next year.

▲ Yuil Robotics = Decided to acquire land and buildings near Cheongna-dong, Seo-gu, Incheon Metropolitan City for 25,997.6 million KRW. This corresponds to 68.32% of total assets.

▲ Daishin Balance No.12 SPAC = Decided to absorb and merge the unlisted company Selbio Humantec. The merger ratio between Selbio Humantec and Daishin Balance No.12 Special Purpose Acquisition Company is 1 to 0.3323363. Upon completion of the merger, Selbio Humantec will be the surviving company and Daishin Balance No.12 SPAC will be the dissolved company. The merger date is March 21 next year, and the record date for shareholders due to the merger is January 10 next year. The period for submitting merger objection notices is from January 30 to February 13 next year.

▲ NanoCamtec = Decided to raise 10 billion KRW in operating funds through a third-party allotment paid-in capital increase. 9,337,068 common shares will be newly issued at a price of 1,071 KRW per share. The third-party allotment recipients are Trinity Equity LLC and Casa Solution. The new shares are scheduled to be listed on March 3 next year.

▲ Makers = Decided to acquire treasury shares of 500,000 common shares to stabilize stock price and enhance shareholder value. The expected acquisition amount is approximately 2.92 billion KRW. The expected acquisition period is from the 18th of this month to January 16 next year.

▲ Melpas = Cheongun Partners Co., Ltd. filed a provisional injunction application for inspection and copying of the shareholder register at the Suwon District Court Seongnam Branch, as disclosed.

▲ UbiVelox = Decided to absorb and merge UbiVelox Mobile. The surviving company is UbiVelox, and the dissolved company is UbiVelox Mobile, with a merger ratio of 1 to 1.0624591. The company explained, "Other than issuing new shares according to the merger ratio to the shareholders of the merged company UbiVelox Mobile, there are no changes related to the governance structure, and there is no change in the largest shareholder." Regarding the purpose of the merger, the company stated, "To ultimately increase corporate value and shareholder value by improving management efficiency."

▲ ISC = Operating profit on a separate basis for the third quarter was 15.071 billion KRW, an increase of 180.1% compared to the same period last year. Sales during the same period increased by 27.2% to 47.599 billion KRW.